Medical Retina Fellowship

NEI临床中心已经进行了许多视网膜医用方案。许多是第一阶段研究，而其他是筛查、评估和治疗方案的研究。这些服务为流行病学和临床应用司进行的试验和流行病学研究提供患者筛查。 这些研究包括：老年性眼病研究(AREDS2)的后续研究和AREDS2后续研究；Lucentis或Avestin(抗血管内皮生长因子治疗)用于治疗糖尿病黄斑水肿；Lucentis用于对老年性黄斑变性进行高速吲哚青绿血管造影术研究；小胶质细胞抑制剂治疗糖尿病视网膜病变和视网膜血管阻塞；中心性浆液性视网膜病变的治疗；以及老年性黄斑变性的遗传学研究。我们也有一个生物库协议，在那里我们可以为一些视网膜血管疾病收集DNA和血液。我们还开始与NINDS合作评估阿尔茨海默病患者的眼底，并与NINDS合作评估HIV相关神经变性患者的HIV眼部发现。

A number of medical retinal protocols have been conducted at the NEI clinical center. Many are phase 1 studies while others are studies in the screening and evaluation and treatment protocol. These provide patients for screening for trials and epidemiologic studies conducted by the Division of Epidemiology and Clinical Applications. These include the followup of Age-Related Eye Disease Study (AREDS2) and AREDS2 follow-up, lucentis or avastin (anti-VEGF therapy) for treatment of diabetic macular edema, while lucentis for a study of high speed indocyanine green angiography for age-related macular degeneration, treatment with microglial inhibitors for diabetic retinopathy and retinovascular occlusions, treatments for central serous retinopathy, and genetic studies of age-related macular degeneration. We have also had a biobank protocol where we would collect DNA and blood for a number of retinovascular diseases. We are also beginning a collaboration with the NINDS on evaluating the fundus of patients with Alzheimer's disease and with NINDS on HIV ocular findings in those with HIV associated neurodegeneration.